Abstract
We examined the efficacy of candesartan in reducing cardiovascular events in hypertensive patients with coexisting chronic kidney disease and cardiovascular diseases. This open-label, prospective study was conducted from 1999 to 2002, and 141 hypertensive subjects 60 to 75 years old with non-diabetic chronic renal insufficiency were enrolled. Before randomization of the patients, we examined their past medical history and found that 69 patients had been hospitalized due to myocardial infarction (MI) or stroke. Therefore, the patients were divided into 2 groups, one with previous histories of MI or stroke and the other with no previous history of MI or stroke. The patients were randomized to receive either the angiotensin receptor blocker candesartan or conventional treatment. The mean duration of follow-up was 3.1±0.4 years. The primary outcome was a primary cardiovascular event (MI, stroke, or heart failure) verified by hospitalization. At the end of the study, in the patients with past history of cardiovascular diseases, blood pressure was reduced from 146.4±7.2/79.2±5.1 to 134.4±6.1/72.3 ±4.0 mmHg in the candesartan group and from 145.3 ±5.1/80.1±3.8 to 133.4±5.8/73.8 ±4.2 mmHg in the conventional treatment group. In the patients without past history of cardiovascular diseases, blood pressure was reduced from 143.2±4.3/78.3±4.8 to 133.8±5.3/73.1±3.8 mmHg in the candesartan group and from 143.9±6.8/78.1±4.2 to 132.6±5.4/74.5±4.4 mmHg in the conventional treatment group at the end of the study. There were no significant differences between the candesartan group and the conventional treatment group in the reduction of blood pressures. Among patients with a past history of cardiovascular disease, the serum creatinine concentration increased from 1.49±0.38 to 1.58±0.42 by candesartan treatment and from 1.50±0.32 to 1.89±0.37 by conventional treatment. On the other hand, in patients with no past history of cardiovascular disease, the serum creatinine concentration increased from 1.44±0.42 to 1.46±0.40 by candesartan treatment and from 1.46±0.44 to 1.51 ±0.38 by conventional treatment. Although, there was no significant difference in the incidence of cardiovascular events between the 2 groups with the candesartan-based and conventional-based antihypertensive treatment, in patients without cardiovascular events (12/36 vs. 7/34: these figures indicate events per total participated persons per 3 years; following figures are the same as this), treatment with candesartan reduced the incidence of cardiovascular events in the patients with past history of cardiovascular diseases (20/33 vs. 32/38). In particular, candesartan-based treatment reduced the incidence of congestive heart failure by 66.4% in these patients. In conclusion, this prospective, open-labeled randomized study suggests that 1) previous history of cardiovascular diseases is a major risk factor for cardiovascular events; and 2) candesartan is effective for reduction of cardiovascular events in hypertensive patients with coexisting chronic kidney disease and cardiovascular diseases, especially for prevention of congestive heart failure.
Similar content being viewed by others
Article PDF
References
Fried L : Renal insufficiency as a predictor of cardiovascular outcomes. J Am Coll Cardiol 2003; 41: 1364–1372.
Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J : The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9–17.
Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.
Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–364.
Jafar TH, Schmid CH, Levey AS : Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med 2002; 137: 298–299.
Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H : Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175–178.
Saruta T, Arakawa K, Iimura O, et al: Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22: 197–202.
Hiwada K, Ogihara T, Matsumoto M, et al: Guidelines for hypertension in the elderly—1999 revised version. Ministry of Health and Welfare of Japan. Hypertens Res 1999; 22: 231–259.
Brenner B, Cooper ME, De Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Iino Y, Hayashi M, Kawamura T, et al: Renoprotective effect of losartan in comparison to amlodipine in patients with chronic kidney disease and hypertension—a report of the Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) study. Hypertens Res 2004; 27: 21–30.
Granger CB, McMurray JJ, Yusuf S, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–776.
Anavekar NS, McMurray JJ, Velazquez EJ, et al: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285–1295.
Foley RN, Herzog CA, Collins AJ : Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784–1790.
Levey AS : Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis 1998; 32: S5–S13.
Suzuki H, Kanno Y, for the Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group : Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307–314.
Cockroft DW, Gault MH : Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
Armitage P, Berry G, Matthews JNS : Survival analysis, in Statistical Methods in Medical Research, 4th ed. Oxford, Blackwell Science, 2002, pp 568–590.
Shlipak MG, Fried LF, Crump C, et al: Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 2002; 62: 997–1004.
Mann J, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE Investigation : Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril; the HOPE randomized trial. Ann Intern Med 2001; 134: 629–636.
Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G : Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 1998; 53: 1209–1216.
Laskar SR, Dries DL : The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr Cardiol Rep 2003; 5: 205–210.
Brewster UC, Setaro JF, Perazella MA : The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326: 15–24.
Hillege HL, Girbes ARJ, de Kam PJ, et al: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203–210.
McMurray JJ, Ostergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771.
Nakamura T, Ushiyama C, Osada S, et al: Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes. Clin Exp Nephrol 2002; 6: 135–139.
Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN : Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999; 99: 2658–2664.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W : Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64: 610–615.
Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.
Suzuki H, Saruta T : Effects of calcium antagonist, benidipine, on the progression of chronic renal failure in the elderly: a 1-year follow-up. Clin Exp Hypertens 2001; 23: 189–201.
Ardizzoni A : Efficient designs for testing new agents and regimens. Chest 1996; 109: 83S–86S.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Nakamura, T., Kanno, Y., Takenaka, T. et al. An Angiotensin Receptor Blocker Reduces the Risk of Congestive Heart Failure in Elderly Hypertensive Patients with Renal Insufficiency. Hypertens Res 28, 415–423 (2005). https://doi.org/10.1291/hypres.28.415
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.415
Keywords
This article is cited by
-
Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
BMC Cardiovascular Disorders (2020)
-
Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials
Hypertension Research (2019)
-
Chapter 7: Blood pressure management in elderly persons with CKD ND
Kidney International Supplements (2012)
-
References
Kidney International Supplements (2012)
-
Vascular compliance is secured under angiotensin inhibition in non-diabetic chronic kidney diseases
Journal of Human Hypertension (2008)